EnBio Holdings, Inc carries a market capitalization of 5.83B, placing it among publicly traded companies globally. Its enterprise value stands at 9.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.83B |
| Enterprise Value | 9.62B |
EnBio Holdings, Inc currently has 8.14M shares outstanding.
| Shares Outstanding | 8.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
EnBio Holdings, Inc trades at a trailing price-to-earnings ratio of 6.37. The price-to-sales ratio is 0.47, and the price-to-book ratio stands at 0.74.
| PE Ratio | 6.37 |
| PS Ratio | 0.47 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, EnBio Holdings, Inc trades at an EV/EBITDA multiple of 11.81 and an EV/FCF ratio of 120.96. The EV/Sales ratio of 1.01 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.81 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.01 |
| EV / EBITDA | 11.81 |
| EV / EBIT | 11.81 |
| EV / FCF | 120.96 |
EnBio Holdings, Inc maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 100.33, indicating elevated leverage, while an interest coverage ratio of 7.11 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.99 |
| Quick Ratio | 0.87 |
| Debt / Equity | 100.33 |
| Debt / EBITDA | 10.57 |
| Interest Coverage | 7.11 |
EnBio Holdings, Inc posts a return on equity of 12.89 and a return on invested capital of 3.38.
| Return on Equity (ROE) | 12.89 |
| Return on Assets (ROA) | 3.87 |
| Return on Invested Capital (ROIC) | 3.38 |
| Return on Capital Employed (ROCE) | 5.28 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.26 |
Over the trailing twelve months, EnBio Holdings, Inc has paid 326.25M in income taxes, reflecting an effective tax rate of 30.61.
| Income Tax | 326.25M |
| Effective Tax Rate | 30.61 |
EnBio Holdings, Inc's stock has gained approximately 14.33121% over the past 52 weeks. The 50-day moving average sits at 769.24, while the 200-day moving average is 682.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.33121% |
| 50-Day Moving Average | 769.24 |
| 200-Day Moving Average | 682.27 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, EnBio Holdings, Inc generated 9.58B in revenue and converted that into 708.76M in net income, yielding earnings per share of 98.70. EBITDA reached 815.16M, while operating income came in at 815.16M.
| Revenue | 9.58B |
| Gross Profit | 2.48B |
| Operating Income | 815.16M |
| Pretax Income | 1.07B |
| Net Income | 708.76M |
| EBITDA | 815.16M |
| EBIT | 815.16M |
| Earnings Per Share (EPS) | 98.70 |
EnBio Holdings, Inc holds 3.60B in cash and equivalents against 8.62B in total debt, resulting in a net debt position of 5.02B. Total book value stands at 6.09B, with working capital of 4.10B providing operational flexibility.
| Cash & Cash Equivalents | 3.60B |
| Total Debt | 8.62B |
| Net Debt | 5.02B |
| Equity (Book Value) | 6.09B |
| Book Value Per Share | 812.18 |
| Working Capital | 4.10B |
EnBio Holdings, Inc operates with a gross margin of 25.94, reflecting its pricing power and cost economics. The operating margin of 8.51 and net profit margin of 7.40 provide insight into operational efficiency.
| Gross Margin | 25.94 |
| Operating Margin | 8.51 |
| Pretax Margin | 11.13 |
| Profit Margin | 7.40 |
| EBITDA Margin | 8.51 |
EnBio Holdings, Inc posts an Altman Z-Score of 1.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.44 |